Form D · Biotechnology
Mulberry Biotherapeutics, Inc.
Wellesley, MA · CIK 0001859602
Offering snapshot reported Apr 30, 2021 · SEC filing
- Reported sold
- $2.12M Offering amount: $2.8M
- Investors reported
- 17 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 19, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 30, 2021 | Initial | $2,117,600 | No comparison | 17 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-397742
Source: Form D, filed Apr 30, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Neil Kirby | Executive |
| Susan Luo | Executive |
| Philip R. Reilly | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
40 Walnut Street, Suite 301
Wellesley, MA, 02481
Wellesley, MA, 02481